Disability measurements were taken at the 2-, 6-, and 12-month time points after enrollment in the MANAS trial. Of the 2491 participants attending the 2-month follow-up, 1024 (41.1%) maintained a diagnosis of CMD. This subsample of 1024 participants was included in the current analysis as a cohort followed from 2 to 6 months after enrollment.
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.
Tips for asking effective questions
+ Description
Write a detailed description. Include all information that will help others answer your question including experimental processes, conditions, and relevant images.